News
SLP
27.92
-2.31%
-0.66
Voya SmallCap Opportunities Portfolio Q3 2024 Commentary
Seeking Alpha · 10h ago
Craig-Hallum Issues a Buy Rating on Simulations Plus (SLP)
TipRanks · 11h ago
Weekly Report: what happened at SLP last week (1216-1220)?
Weekly Report · 16h ago
SIMULATIONS PLUS ANNOUNCES FIRST QUARTER FISCAL YEAR 2025 EARNINGS AND CONFERENCE CALL DATE
Reuters · 6d ago
Miller-Howard Small Cap Dividend Q3 2024 Commentary
Seeking Alpha · 6d ago
Weekly Report: what happened at SLP last week (1209-1213)?
Weekly Report · 12/16 09:22
US Growth Stocks With High Insider Ownership For December 2024
Simply Wall St · 12/13 11:13
Adobe Systems (ADBE) Q4 Earnings and Revenues Beat Estimates
NASDAQ · 12/11 22:15
Weekly Report: what happened at SLP last week (1202-1206)?
Weekly Report · 12/09 09:21
Synopsys (SNPS) Q4 Earnings and Revenues Top Estimates
NASDAQ · 12/04 22:15
Simulations Plus management to meet with Craig-Hallum
TipRanks · 12/04 16:45
Weekly Report: what happened at SLP last week (1125-1129)?
Weekly Report · 12/02 09:21
Invesco Small Cap Equity Fund Q3 2024 Commentary
Seeking Alpha · 11/27 13:05
Wall Street Analysts Predict a 56.99% Upside in Simulations Plus (SLP): Here's What You Should Know
NASDAQ · 11/26 14:55
Weekly Report: what happened at SLP last week (1118-1122)?
Weekly Report · 11/25 09:20
Simulations Plus (SLP) Stock Jumps 8.9%: Will It Continue to Soar?
NASDAQ · 11/22 12:15
Weekly Report: what happened at SLP last week (1111-1115)?
Weekly Report · 11/18 09:19
Simulations Plus Price Target Announced at $39.00/Share by Stephens & Co.
Dow Jones · 11/15 19:03
Simulations Plus Initiated at Overweight by Stephens & Co.
Dow Jones · 11/15 19:03
Stephens & Co. Initiates Coverage On Simulations Plus with Overweight Rating, Announces Price Target of $39
Benzinga · 11/15 18:53
More
Webull provides a variety of real-time SLP stock news. You can receive the latest news about Simulations Plus Inc through multiple platforms. This information may help you make smarter investment decisions.
About SLP
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The Company’s comprehensive bio simulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. It operates through two segments: software and services. It offers software products for pharmaceutical research, development, and commercialization, including GastroPlus, DDDPlus, MembranePlus, ADMET Predictor, MedChem Designer, DILIsym, NAFLDsym, ILDsym, IPFsym and others. In addition, it also delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development.